These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 24951771)

  • 1. Are hemodynamics surrogate end points in pulmonary arterial hypertension?
    Ventetuolo CE; Gabler NB; Fritz JS; Smith KA; Palevsky HI; Klinger JR; Halpern SD; Kawut SM
    Circulation; 2014 Aug; 130(9):768-75. PubMed ID: 24951771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical and hemodynamic characteristics and possibilities for therapy in patients with severe (functional class IV) pulmonary arterial hypertension associated with diffuse connective tissue diseases].
    Nikolaeva EV; Yudkina NN; Kurmukov IA; Novikova DS; Markelova EI; Volkov AV
    Ter Arkh; 2015; 87(5):24-32. PubMed ID: 26155616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials.
    Blette BS; Moutchia J; Al-Naamani N; Ventetuolo CE; Cheng C; Appleby D; Urbanowicz RJ; Fritz J; Mazurek JA; Li F; Kawut SM; Harhay MO
    Lancet Respir Med; 2023 Oct; 11(10):873-882. PubMed ID: 37230098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline Sex Differences in Pulmonary Arterial Hypertension Randomized Clinical Trials.
    Ventetuolo CE; Moutchia J; Baird GL; Appleby DH; McClelland RL; Minhas J; Min J; Holmes JH; Urbanowicz RJ; Al-Naamani N; Kawut SM
    Ann Am Thorac Soc; 2023 Jan; 20(1):58-66. PubMed ID: 36053665
    [No Abstract]   [Full Text] [Related]  

  • 5. Hemodynamic Thresholds for Precapillary Pulmonary Hypertension.
    Gerges C; Gerges M; Skoro-Sajer N; Zhou Y; Zhang L; Sadushi-Kolici R; Jakowitsch J; Lang MB; Lang IM
    Chest; 2016 Apr; 149(4):1061-73. PubMed ID: 26501411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension.
    Weatherald J; Boucly A; Chemla D; Savale L; Peng M; Jevnikar M; Jaïs X; Taniguchi Y; O'Connell C; Parent F; Sattler C; Hervé P; Simonneau G; Montani D; Humbert M; Adir Y; Sitbon O
    Circulation; 2018 Feb; 137(7):693-704. PubMed ID: 29070502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sildenafil therapy for pulmonary hypertension: a prospective study].
    Lu XL; Xiong CM; Shan GL; Liu ZH; Ni XH; Cheng XS; Gu Q; Zhao ZH; Zeng WJ; Zhu F; He JG
    Zhonghua Jie He He Hu Xi Za Zhi; 2011 Jun; 34(6):419-23. PubMed ID: 21781512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials.
    Gabler NB; French B; Strom BL; Palevsky HI; Taichman DB; Kawut SM; Halpern SD
    Circulation; 2012 Jul; 126(3):349-56. PubMed ID: 22696079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
    Steele P; Strange G; Wlodarczyk J; Dalton B; Stewart S; Gabbay E; Keogh A
    BMC Cardiovasc Disord; 2010 Feb; 10():9. PubMed ID: 20170553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Clinical Worsening End Points as a Surrogate for Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Tremblay É; Gosselin C; Mai V; Lajoie AC; Kilo R; Weatherald J; Lacasse Y; Bonnet S; Lega JC; Provencher S
    Circulation; 2022 Aug; 146(8):597-612. PubMed ID: 35862151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics.
    Siehr SL; Ivy DD; Miller-Reed K; Ogawa M; Rosenthal DN; Feinstein JA
    J Heart Lung Transplant; 2013 May; 32(5):546-52. PubMed ID: 23453572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
    Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost.
    Han X; Zhang Y; Dong L; Fang L; Chai Y; Niu M; Yu Y; Liu L; Yang X; Qu S; Li S
    Respir Care; 2017 Apr; 62(4):489-496. PubMed ID: 28119496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy.
    Bhatia S; Frantz RP; Severson CJ; Durst LA; McGoon MD
    Mayo Clin Proc; 2003 Oct; 78(10):1207-13. PubMed ID: 14531479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Study of Acute Vasoreactivity Testing in Patients with Chronic Thromboembolic Pulmonary Hypertension.
    Xu QX; Yang YH; Geng J; Zhai ZG; Gong JN; Li JF; Tang X; Wang C
    Chin Med J (Engl); 2017 Feb; 130(4):382-391. PubMed ID: 28218209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of right ventricular Tei-index for assessing disease severity and determining response to treatment in patients with pulmonary arterial hypertension.
    Ogihara Y; Yamada N; Dohi K; Matsuda A; Tsuji A; Ota S; Ishikura K; Nakamura M; Ito M
    J Cardiol; 2014 Feb; 63(2):149-53. PubMed ID: 24012334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
    Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost AE; Engel PJ; Kramer MR; Burgess G; Collings L; Cossons N; Sitbon O; Badesch DB;
    Ann Intern Med; 2008 Oct; 149(8):521-30. PubMed ID: 18936500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis.
    Frost AE; Badesch DB; Miller DP; Benza RL; Meltzer LA; McGoon MD
    Chest; 2013 Nov; 144(5):1521-1529. PubMed ID: 23907471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the Need for Upfront Combination Therapy in Pulmonary Arterial Hypertension.
    Bajwa AA; Qureshi T; Shujaat A; Seeram V; Jones LM; Al-Saffar F; Cury JD
    J Cardiovasc Pharmacol Ther; 2015 Jul; 20(4):395-400. PubMed ID: 25613465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence-based pharmacologic management of pulmonary arterial hypertension.
    Benedict N; Seybert A; Mathier MA
    Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.